Potential Use of Cellular Stromal Vascular Fraction in Post-COVID-19 Injury and Respiratory Distress

Posted in Clinical Trials & Pilot Studies, Ideas & Innovations | 1 minute read

June 2nd, 2020

SDARTs faculty member, Robert W. Alexander, MD, DDS, is the Principle Investigator on a first-in-human clinical trial to treat post-COVID 19 survivors with AD cSVF.

Many moderate to severe post-COVID 19 survivors experience compromised lung function. As a proposed solution, adipose-derived cellular stromal vascular fraction (AD cSVF) may be effective in reversing residual damage to the lungs and gas exchange functions.

This article was published in the Journal of Current Medical Research and Opinion.

Want to learn more from Dr. Alexander?

Visit the SDARTs Online Learning Center >